Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...

Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving ...

Rosen's excitement about AI stems from the ability to move beyond population health theories to deliver truly individualized ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

CUTNETs aims to improve surgical evidence for NETs by identifying high-risk patients and developing resectability criteria. Collaboration is essential due to the uncommon nature of NETs and the need ...

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies. The FDA has granted orphan drug designation to ZEN-3694, a novel oral ...

For lenvatinib (Lenvima), which can cause hypertension, patients’ baseline blood pressure should be considered, and they should be monitored for the first 4 to 6 weeks. He recommends oncologists ...

Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The ...

Grewal, MD, assistant professor at the Winship Cancer Institute at Emory University discusses the significant and concerning ...